Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ProMetic Life Sciences -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (59)	1/10/2017 9:33:29 PM
From: Leo Fisher	Read Replies (1) \| Respond to of 250

Peanuts to reacquire rights, modest royalty going forward. -Hematech most likely did not meet the strict manufacturing standards set in the “CMO relationship” instead of facing fines etc. they settled for some stock and a little royalty. ADMA had this issue with RI002 the "FDA identified in the CRL certain outstanding inspection issues and deficiencies at ADMA’s third-party contract manufacturers, including its contract drug substance and product manufacturer, its contract fill and finisher and compliance issues with a third-party contract testing laboratory, and requested documentation of corrections for a number of those issues." I am guessing that is what PLI is trying to avoid during the BLA. From what I gather when it comes to the Plasma business purity and cleanliness is key. Lock up on shares? -Anyone deep dive this? Projected margins? - "Scuttlebutt" tells me that marketing/sales cost for these things are low due to the small number of patients PLI quotes 1.6 per 1million for Type 1 deficiency; not really to sure on the plasminogen diabetic wound healing, although if it works how much marketing does it need? Use this or lose your leg; not a hard sell. I don't recall management talking margins; does anyone else recall? I haven't had a chance to listen to their conference calls. All thoughts welcome. -LF